CHEST Immersion Severe Asthma May 29-30, 2024-Phenotype and Biomarker-Mosnaim

Phenotype and Biomarker-Mosnaim

Pdf Summary

The document discusses asthma, focusing on pathophysiology, phenotypes, and biomarkers. It highlights the heterogeneity of asthma, the role of cytokines like IL-4, IL-5, and IL-13, and the importance of determining patient phenotypes for effective management. Various biomarkers such as blood eosinophils and FeNO are associated with exacerbation risk. The text emphasizes the complex gene-environment interactions influencing asthma, including early-life determinants and the impact of factors like allergens, pollution, obesity, and genetics.<br /><br />It delves into specific types of asthma like Aspirin-Exacerbated Respiratory Disease and Exercise-Induced Bronchoconstriction, discussing their manifestations and treatments. The link between obesity and asthma is explored, noting the negative effects of excess weight on asthma control and response to therapy. Key concepts such as antigens, antibodies, and cytokines in asthma are also explained.<br /><br />The document underscores the importance of identifying asthma phenotypes and endotypes for personalized therapy using biomarkers like IgE, blood eosinophils, and FeNO. It mentions potential biomarkers under study and provides an overview of available biomarkers for Type 2 asthma. The aim is to utilize biomarkers to guide targeted therapies effectively in managing asthma. The text concludes with a summary of key points and a list of references for further reading on asthma management and biomarkers.

Keywords

asthma

pathophysiology

phenotypes

biomarkers

cytokines

IL-4

IL-5

IL-13

heterogeneity

exacerbation risk